Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Smr3.5

Sermorelin – Forschung

Überwiegend Mechanismus / Beobachtung

11 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Sermorelin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 1986–2026 mit einer typischen Studiengröße von 19 Teilnehmenden.

Basierend auf 11 Studien · 6 RCTs · 257 Teilnehmende insgesamt

Konfidenz

Mittlere Konfidenz

Nach Outcome

Growth hormone axis & GH deficiency
Überwiegend Mechanismus / Beobachtung10 Studien
Aging & GH-axis restorationWird über GH/IGF-1 als "Anti-Aging" vermarktet, doch ein Nutzen für Langlebigkeit oder Gesundheitsspanne ist nicht belegt; lediglich der GH-Sekretionsmechanismus ist etabliert. · Nicht etabliert
Überwiegend Mechanismus / Beobachtung4 Studien
Safety profile
Zu wenige bewertete Studien1 Studie

Lässt nach

Nur 1 Studie in den letzten 5 Jahren

198620062026

1Systematische Übersicht2026

We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect.

Mendias CL, Awan TM. · Sports medicine (Auckland, N.Z.) (2026)

Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.
This narrative review focuses on the utilization of peptides in sports medicine, and alternative treatments that may be considered.
We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance.

Quelle ansehen

2Open-Labeln=110 · medium study1996

GHRH administered as a once daily dose of 30 micrograms/kg GHRH-(1-29), s.c., was effective in increasing height velocity in GH-deficient children.

Thorner M, Rochiccioli P, Colle M, Lanes R, et al. · J Clin Endocrinol Metab (1996)

Multicenter open-label study of 110 previously untreated prepubertal GH-deficient children given 30 µg/kg/day GHRH(1-29) sc at bedtime for up to 1 year
Mean height velocity rose from 4.1 cm/yr at baseline to 7.2 cm/yr at 12 months; 74% rated good responders at 6 months
No adverse changes in glucose or excessive IGF-1 generation; overall well tolerated

Quelle ansehen

3RCTn=43 · small study1993

Height velocity during treatment was lowest in the LD group, but comparable in the HD and GH groups.

Neyzi O, Yordam N, Ocal G, Bundak R, et al. · Acta Paediatr Suppl (1993)

Randomized comparison in 43 prepubertal children with hypothalamic GH deficiency: low-dose (30 µg/kg/day) vs high-dose (60 µg/kg/day) GHRH(1-29) vs recombinant GH for 6 months
An increase in height velocity of ≥2 cm/yr occurred in all but two children
Height velocity on high-dose GHRH(1-29) was comparable to GH, but an increase in height SDS for bone age occurred only in the GH-treated group

Quelle ansehen

4Übersicht1986

Several analogues of GHRH have been shown to be safe, sensitive and specific stimuli to GH release.

Grossman A, Savage MO, Besser GM. · Clin Endocrinol Metab (1986)

Review of GHRH biology: the active C-terminal-shortened derivatives (including the 29-residue fragment) retain GH-releasing activity
Exogenous GHRH specifically increases circulating GH and may increase growth long-term
Many children with GH deficiency respond to intravenous GHRH with an acute rise in serum GH

Quelle ansehen

5RCTn=32 · small study2005

Administration of PEG-GHRH generated a clear increase in circulating GH compared with placebo... Some impairment of glucose tolerance was observed in the elderly following repeated administration.

Munafo A, Nguyen TX, Papasouliotis O, Lécuelle H, et al. · Eur J Endocrinol (2005)

Phase I randomized placebo-controlled trial of a PEGylated GHRH (designed to extend the short GHRH(1-29) half-life) in 12 young men and 20 elderly men/women
Subcutaneous dosing raised circulating GH and IGF-1 vs placebo; injection-site reactions were mild and transient
Repeated dosing in the elderly impaired glucose tolerance — a relevant safety signal for GH-axis stimulation

Quelle ansehen

6Open-Labeln=16 · very small study1988

Growth hormone remains the treatment of choice in growth hormone insufficiency.

Smith PJ, Brook CG. · Arch Dis Child (1988)

16 prepubertal GH-insufficient children treated with subcutaneous GHRH (1-40 and 1-29) for ~9 months each
73% (GHRH 1-40) and 63% (GHRH 1-29) showed a growth response; double the GHRH 1-29 dose was needed to match pulsatile GHRH 1-40
Response to conventional GH treatment was significantly better than GHRH, and height velocity improved when children were switched to GH

Quelle ansehen

7RCTn=19 · very small study1997

The use of GHRH or its analogs may be an alternative mode for restoring the GH-IGF-I axis in aging individuals.

Khorram O, Laughlin GA, Yen SS. · J Clin Endocrinol Metab (1997)

Single-blind, randomized, placebo-controlled 5-month trial in 19 adults aged 55-71, self-injecting [Nle27]GHRH(1-29)-NH2 10 µg/kg nightly
Tested whether restoring the GH/IGF-1 axis in aging is feasible with a GHRH analog rather than recombinant GH
Frames the aging/'anti-aging' question as a hypothesis about GH-axis restoration — not a demonstration of clinical anti-aging benefit

Quelle ansehen

8RCTn=19 · very small study1997

Restoration of this axis in age-advanced individuals, by the administration of GHRH, may enhance immune cell function.

Khorram O, Yeung M, Vu L, Yen SS. · J Clin Endocrinol Metab (1997)

Single-blind randomized placebo-controlled 5-month trial in 19 elderly adults given [Nle27]GHRH(1-29)-NH2 10 µg/kg nightly
Examined lymphocyte subsets, NK-cell number/cytotoxicity, mitogen responses, and IL-2 measures alongside IGF-1
Explored an immune-restoration hypothesis tied to GH/IGF-1 axis support in aging

Quelle ansehen

9RCTn=10 · very small study2000

Significantly lower peak and area under the curve (AUC) GH concentrations occurred in the irradiated group.

Achermann JC, Brook CG, Hindmarsh PC. · Eur J Endocrinol (2000)

Randomized controlled study comparing GHRH(1-29)NH2 dose-response (0.05, 0.15, 1.0 µg/kg iv) in 5 post-cranial-irradiation GH-insufficient adults vs 5 matched controls
Irradiated patients had significantly lower peak and AUC GH responses at clinically relevant doses
Refines the diagnostic use of GHRH(1-29) and the pathophysiology of post-radiotherapy GH insufficiency

Quelle ansehen

10RCTn=8 · very small study1995

Peak GH levels in response to GHRH1-29NH2, GHRP-2 and the combined... administrations were observed between 20 and 45 minutes.

Tiulpakov AN, Brook CG, Pringle PJ, Peterkova VA. · Clin Endocrinol (Oxf) (1995)

Randomized crossover pharmacodynamic study in 8 healthy adult men comparing GHRH(1-29)NH2, GHRP-2, and their combination (each 1 µg/kg iv)
GHRH(1-29) produced a clear GH peak at 20-45 minutes, though lower than GHRP-2 or the combination
Characterizes the magnitude and time-course of the GH response to GHRH(1-29) in healthy adults

Quelle ansehen

11Open-Label1986

It is proposed that GRF testing could provide a useful additional tool in the diagnosis of hGH deficiency.

Ranke MB. · Acta Paediatr Scand Suppl (1986)

Early clinical experience with synthetic GHRH(1-29) (GRF) in healthy volunteers and children with various disorders
Healthy subjects secreted GH up to ~40 ng/ml; GH-deficient children showed much lower responses than non-deficient children
Low false-positive rate supported GHRH testing as a diagnostic tool for GH deficiency

Quelle ansehen

In der Forschungsbibliothek ansehen

Sermorelin – Forschung

Überwiegend Mechanismus / Beobachtung

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.

Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone.

Growth hormone releasing hormone.

Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.

Growth hormone releasing hormone or growth hormone treatment in growth hormone insufficiency?

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.

Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.

The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency.

GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers.

Clinical experience with GRF.